Alkermes PLC

NAS: ALKS

GO
/marketstate/country/us

Before the Bell

 --Quotes are delayed by 20 min

Mar 1, 2021, 8:43 a.m.

/zigman2/quotes/205084517/composite

$

19.04

Change

0.00 0.00%

Volume

Volume 10

Quotes are delayed by 20 min

/zigman2/quotes/205084517/composite

Previous close

$ 19.04

$ 19.04

Change

-0.40 -2.06%

Day low

Day high

$18.52

$19.91

Open

52 week low

52 week high

$11.98

$23.92

Open

Insider Actions for Alkermes PLC

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/21/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
14,386   Derivative/Non-derivative trans. at $19.58 per share. 281,677
02/21/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
2,587   Derivative/Non-derivative trans. at $19.58 per share. 50,653
02/21/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
2,022   Derivative/Non-derivative trans. at $19.58 per share. 39,590
02/21/2021 Blair C. Jackson
EVP, Chief Operating Officer
1,412   Derivative/Non-derivative trans. at $19.58 per share. 27,646
02/21/2021 Iain Michael Brown
SVP, Chief Financial Officer
1,412   Derivative/Non-derivative trans. at $19.58 per share. 27,646
02/21/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
2,022   Derivative/Non-derivative trans. at $19.58 per share. 39,590
02/21/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
32,400   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
6,875   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 Blair C. Jackson
EVP, Chief Operating Officer
4,800   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 Iain Michael Brown
SVP, Chief Financial Officer
4,800   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
6,875   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
5,825   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
5,353   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
7,036   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Blair C. Jackson
EVP, Chief Operating Officer
4,589   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Iain Michael Brown
SVP, Chief Financial Officer
4,589   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
10,095   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 C. Todd Nichols
SVP, Chief Commercial Officer
3,824   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
2,360   Derivative/Non-derivative trans. at $19.58 per share. 46,208
02/20/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
2,061   Derivative/Non-derivative trans. at $19.58 per share. 40,354
02/20/2021 Blair C. Jackson
EVP, Chief Operating Officer
1,374   Derivative/Non-derivative trans. at $19.58 per share. 26,902
02/20/2021 Iain Michael Brown
SVP, Chief Financial Officer
1,378   Derivative/Non-derivative trans. at $19.58 per share. 26,981
02/20/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
3,064   Derivative/Non-derivative trans. at $19.58 per share. 59,993
02/20/2021 C. Todd Nichols
SVP, Chief Commercial Officer
1,292   Derivative/Non-derivative trans. at $19.58 per share. 25,297
02/17/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
3,869   Derivative/Non-derivative trans. at $19.97 per share. 77,263
02/17/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
1,492   Derivative/Non-derivative trans. at $19.97 per share. 29,795
02/17/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
868   Derivative/Non-derivative trans. at $19.97 per share. 17,333
02/17/2021 Blair C. Jackson
EVP, Chief Operating Officer
781   Derivative/Non-derivative trans. at $19.97 per share. 15,596
02/17/2021 Iain Michael Brown
SVP, Chief Financial Officer
868   Derivative/Non-derivative trans. at $19.97 per share. 17,333
02/17/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
8,750   Derivative/Non-derivative trans. at $0 per share. 0
02/17/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
3,000   Derivative/Non-derivative trans. at $0 per share. 0
02/17/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
2,500   Derivative/Non-derivative trans. at $0 per share. 0
02/17/2021 Blair C. Jackson
EVP, Chief Operating Officer
2,250   Derivative/Non-derivative trans. at $0 per share. 0
02/17/2021 Iain Michael Brown
SVP, Chief Financial Officer
2,500   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
8,074   Derivative/Non-derivative trans. at $19.79 per share. 159,784
02/16/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
1,678   Derivative/Non-derivative trans. at $19.79 per share. 33,207
02/16/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
1,172   Derivative/Non-derivative trans. at $19.79 per share. 23,193
02/16/2021 Blair C. Jackson
EVP, Chief Operating Officer
825   Derivative/Non-derivative trans. at $19.79 per share. 16,326
02/16/2021 Iain Michael Brown
SVP, Chief Financial Officer
825   Derivative/Non-derivative trans. at $19.79 per share. 16,326
02/16/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
1,172   Derivative/Non-derivative trans. at $19.79 per share. 23,193
02/16/2021 Richard F. Pops
Director and CEO, Alkermes plc; Director
18,125   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
3,375   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
3,375   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Blair C. Jackson
EVP, Chief Operating Officer
2,375   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Iain Michael Brown
SVP, Chief Financial Officer
2,375   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
3,375   Derivative/Non-derivative trans. at $0 per share. 0
01/13/2021 Wendy L. Dixon
Director
20,000   Derivative/Non-derivative trans. at $12.62 per share. 252,400
01/13/2021 Wendy L. Dixon
Director
15,000   Derivative/Non-derivative trans. at $12.62 per share. 189,300
10/01/2020 Paul J. Mitchell
Director
20,000   Disposition at $16.61 per share. 332,200
10/01/2020 Paul J. Mitchell
Director
20,000   Derivative/Non-derivative trans. at $14.92 per share. 298,400
09/28/2020 David Westbrook Anstice
Director
17,832   Disposition at $16.78 per share. 299,220
09/28/2020 David Westbrook Anstice
Director
20,000   Derivative/Non-derivative trans. at $14.92 per share. 298,400
07/14/2020 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc.
5,523   Derivative/Non-derivative trans. at $18.1 per share. 99,966
06/07/2020 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
368   Derivative/Non-derivative trans. at $17.19 per share. 6,325
06/07/2020 Craig C. Hopkinson
EVP R&D, Chief Medical Officer
1,250   Derivative/Non-derivative trans. at $0 per share. 0
06/05/2020 David Jose Gaffin
SVP, CLO, Alkermes, Inc.
1,000   Gift at $0 per share. 0
06/05/2020 C. Todd Nichols
SVP, Chief Commercial Officer
1,029   Derivative/Non-derivative trans. at $17.19 per share. 17,688
06/05/2020 C. Todd Nichols
SVP, Chief Commercial Officer
3,500   Derivative/Non-derivative trans. at $0 per share. 0

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
25 Purchases
23 Sales
184,061
56,994
Last 6 months
27 Purchases
25 Sales
224,061
94,826
Last 12 months
41 Purchases
39 Sales
658,567
496,473

Officers and Executives

Mr. Richard F. Pops
Chairman & Chief Executive Officer
Mr. Blair C. Jackson
Chief Operating Officer & Executive Vice President
Mr. Iain Michael Brown
Senior VP, Chief Financial & Accounting Officer
Ms. Sondra Smyrnios
Senior Vice President-Clinical Operations
Dr. Kanchan Relwani
Senior Vice President-Medical Affairs
Dr. Craig C. Hopkinson
Chief Medical Officer & EVP-Research & Development
Mr. Thomas Harvey
Chief Information Officer & Senior VP-IT
Dr. Niels Borgstein
SVP-Late Stage Clinical Development
Mr. Michael J. Landine
Chief Risk Officer & SVP-Corporate Development
Mr. David Jose Gaffin
Secretary, Chief Legal & Compliance Officer, SVP
Mr. Declan O’Connor
SVP-Operations, Quality & Safety
Mr. C. Todd Nichols
Chief Commercial Officer & Senior Vice President
Mr. Shane M. Cooke
Director
Ms. Alexandria Braun
Head-Investor Relations
Mr. Stephen Schiavo
Senior Vice President-Human Resources
Ms. Heather Faulds
SVP-Regulatory Affairs & Knowledge Management
Mr. Peter Norman
Senior VP-Government Relations & Policy
Dr. Richard B. Gaynor
Independent Director
Mr. Frank Anders Wilson
Independent Director
Mr. David Antonio Daglio
Independent Director
Mr. Brian Patrick McKeon
Independent Director
Mr. David Westbrook Anstice
Lead Independent Director
Mr. Robert A. Breyer
Independent Director
Dr. Wendy L. Dixon
Independent Director
Mr. Paul J. Mitchell
Independent Director
Ms. Nancy J. Wysenski
Independent Director
Dr. Nancy L. Snyderman
Independent Director
Link to MarketWatch's Slice.